Bruno Antonio, Pandolfo Gianluca, Crucitti Manuela, Cacciola Massimo, Santoro Vincenza, Spina Edoardo, Zoccali Rocco A, Muscatello Maria R A
Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of MessinaMessina, Italy.
Department of Clinical and Experimental Medicine, University of MessinaMessina, Italy.
Front Pharmacol. 2017 Apr 11;8:197. doi: 10.3389/fphar.2017.00197. eCollection 2017.
The nutraceutical approach to the management of metabolic syndrome (MetS) might be a promising strategy in the prevention of cardio-metabolic risk. Low-dose bergamot-derived polyphenolic fraction (BPF) has been proven effective in patients with MetS, as demonstrated by a concomitant improvement in lipemic and glycemic profiles. The present study was aimed to further explore, in a sample of subjects receiving second generation antipsychotics (SGAs), the effects on body weight and metabolic parameters of a low dose of BPF (500 mg/day) administered for 60 days. Twenty-eight outpatients treated with SGAs assumed BPF at single daily dose of 500 mg/day for 60 days. Body weight, BMI, fasting levels of glucose, total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol and triglycerides were determined; moreover, Brief Psychiatric Rating Scale (BPRS) was administered. Low-dose BPF administration did not change clinical and metabolic parameters, as well as clinical symptoms in the study sample. At the end of the trial, among completers ( = 24) only nine patients (37.5%) reached an LDL reduction >0 but <50%. Our results demonstrate that patients treated with SGAs may need higher BPF doses for obtaining the positive effects on body weight and metabolic parameters previously found in the general population at lower doses.
采用营养保健品方法管理代谢综合征（MetS）可能是预防心血管代谢风险的一种有前景的策略。低剂量佛手柑衍生的多酚组分（BPF）已被证明对MetS患者有效，血脂和血糖状况的同步改善证明了这一点。本研究旨在进一步探讨，在接受第二代抗精神病药物（SGA）治疗的受试者样本中，连续60天给予低剂量BPF（500毫克/天）对体重和代谢参数的影响。28名接受SGA治疗的门诊患者每天服用一次500毫克/天的BPF，持续60天。测定体重、体重指数、空腹血糖、总胆固醇、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇和甘油三酯水平；此外，还使用了简明精神病评定量表（BPRS）。低剂量BPF给药并未改变研究样本中的临床和代谢参数以及临床症状。在试验结束时，在完成试验的患者（n = 24）中，只有9名患者（37.5%）的低密度脂蛋白降低幅度>0但<50%。我们的结果表明，接受SGA治疗的患者可能需要更高剂量的BPF才能获得先前在普通人群中较低剂量时发现的对体重和代谢参数方面的积极效果。
